CD19 Antibody (2E2) Summary
| Immunogen |
Purified recombinant fragment from the extracellular domain of the human CD19 protein expressed in E. Coli.
|
| Isotype |
IgG1
|
| Clonality |
Monoclonal
|
| Host |
Mouse
|
| Gene |
CD19
|
| Purity |
Unpurified
|
| Innovators Reward |
Test in a species/application not listed above to receive a full credit towards a future purchase.
Learn about the Innovators Reward
|
Applications/Dilutions
| Dilutions |
|
| Application Notes |
The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
|
| Theoretical MW |
61 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors. |
Packaging, Storage & Formulations
| Storage |
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
|
| Buffer |
Ascites
|
| Preservative |
0.03% Sodium Azide
|
| Purity |
Unpurified
|
Alternate Names for CD19 Antibody (2E2)
- B4
- B-lymphocyte antigen CD19
- B-lymphocyte surface antigen B4
- CD19 antigen
- CD19 molecule
- CD19
- CVID3
- Differentiation antigen CD19
- Leu-12
- MGC12802
- T-cell surface antigen Leu-12
Background
The CD19 antigen (95kDa) is expressed from the earliest stage of B progenitor development, on all peripheral B cells including germinal centre B cells, and all B cell lines and B cell leukaemia tested. T cell and monocytic cell lines are negative and the antigen is lost on B cell maturation to plasma cells. The antigen is a type I integral membrane glycoprotein whose in vitro inhibition will influence B cell activation and proliferation.
